Propanc Biopharma Files Fourth Provisional Patent In Two Months, Boosting Global Protection For Its Breakthrough Proenzyme Cancer Formulations

Propanc Biopharma, Inc., a biopharmaceutical company focused on developing innovative treatments for chronic diseases, including recurrent and metastatic cancers, announced the filing of its fourth provisional patent application in the past two months with IP Australia. This latest application centers on novel formulations of the pancreatic proenzymes, trypsinogen and chymotrypsinogen, which are the active components of Propanc’s lead asset, PRP. The new formulations address critical challenges in stability, storage, freeze/thaw cycles, and global transport, overcoming longstanding barriers to developing viable pharmaceutical compositions of these proenzymes for cancer and other chronic disease therapies.

“Filing four provisional patent applications in such a short timeframe highlights our commitment to protecting and expanding our groundbreaking proenzyme technology,” said James Nathanielsz, CEO of Propanc. “As these applications progress to national phase entry in major global markets, we expect our intellectual property portfolio to grow from roughly 90 patents to over 200, covering compositions, formulations, treatment methods, and new therapeutic indications.”

This rapid expansion of intellectual property strengthens Propanc’s leadership in a unique therapeutic approach that uses proenzymes to target and prevent metastasis from solid tumors. This strategy is particularly relevant for aggressive, poorly differentiated cancers, where treatment options are limited and conventional therapies often cause severe side effects.

“These patent applications will secure our leadership in this field for the next two decades,” Mr. Nathanielsz added. “They lay a strong foundation to advance PRP into a Phase 1b First-In-Human study for patients with advanced cancer. Preparations are moving quickly, and we anticipate additional updates on our clinical progress and broader pipeline in the near future.”

Propanc’s PRP is a proprietary intravenous formulation designed to selectively target cancer stem cells and circulating tumor cells while sparing healthy tissue. The therapy has the potential to provide a long-term treatment option that prevents recurrence and metastasis without the toxic side effects often associated with chemotherapy or radiation.